Leon-nanodrugs and Instillo work together to tackle formulations issues
MJR technology offers reformulation options that can lead to a superior profile for an API.
Leon-nanodrugs and Instillo are set to work together for the production of a generic oncology product using leon-nanodrugs’ proprietary nanotechnology platform – MicroJet Reactor (MJR). The product will be manufactured at Ursapharm Arzneimittel in Saarbrücken, Germany.
It is estimated that over 60% of pharmaceutical APIs are poorly soluble in water. Leon’s MJR technology offers reformulation options that not only address this issue, but can also lead to a superior profile for the API by increasing bioavailability, reducing inter patient variability, improving onset of action, etc. The one-step, bottom up, continuous precipitation process approach of the MJR technology is highly cost effective and easily scalable.
Dr Theron E. Odlaug, CEO of leon-nanodrugs and the US subsidiary explains: “The vision of leon- nanodrugs is to be recognized as a global leader in nanotechnology-formulated pharmaceuticals through contract services and co-development partnerships. Through the unique attributes of our MJR technology, our goal is to generate added value to both established molecules and novel NCEs. We will be seeking a commercial partner for the product once we have shown bioequivalence.”
Dr Bernd Baumstümmler, CEO of Instillo states: “Instillo Group bring experts from different areas together for the ultimate support for our customers in a range of pharmaceutical services from development through registration to commercialization by the companies MJR PharmJet and Quasaar. Quasaar takes over the GMP-relevant aspects of drug and formulation development and brings the products forward in the path of commercialization.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.